Our Story
StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) is a global, vertically integrated healthcare company dedicated to improving outcomes for cancer and other chronic diseases through early detection and intervention. We deliver this through a comprehensive, physician supervised telehealth program which uses advanced diagnostics to help detect cancer and chronic disease in the earliest stages when they are highly treatable, along with lifestyle and pharmaceutical management.
Pioneers in Liquid Biopsy
As early pioneers in liquid biopsies, we developed one of the first blood-based biomarker tests for the early identification of Colorectal Cancer. ColonSentry® uses our proprietary Sentinel Principle technology which is based on the scientific observation that circulating blood reflects, in a detectable way, what is occurring throughout the body. StageZero's Sentinel Principle® technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America. The Company's next generation test, Aristotle™, is the first mRNA-based, multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer.
|
Our LaboratoryOur laboratory in Richmond, VA is registered and certified according to the Clinical Laboratory Improvement Amendment (CLIA) for high complexity laboratory testing through the Centers of Medicare and Medicaid Services (CMS). In addition, the lab is accredited through the College of American Pathologists (CAP). These certifications demonstrate our highest commitment to excellence in laboratory test processing and our passion for patient care.
|
Our TestsThe Company's next generation test, Aristotle®, is the first multi-cancer panel for simultaneously screening for the molecular signatures of multiple cancers from a single sample of blood. In addition to Aristotle®, we provide individual testing for Colorectal Cancer risk (ColonSentry®), Breast Cancer risk (BreastSentry), and Prostate Cancer risk (The Prostate Health Index). In addition, the Company is also leveraging its specialty in polymerase chain reaction (PCR) testing to provide COVID-19 PCR testing (swab and saliva) and Antibody Testing (blood analysis).
|
|
Our Care
Our wholly owned subsidiary, Care Oncology, Inc. provides a unique telehealth platform to deliver two revolutionary programs.
U.S. Physician services are delivered by Care Oncology Physicians, P.C.
U.K Physician services are delivered by The Care Oncology Clinic in London. 
|
The COC Protocol
The COC Protocol is a telehealth clinical service that offers professionally guided adjunctive care for patients living with cancer. The COC Protocol is designed to work primarily by restricting the overall ability of cancer cells to take up and use (i.e., ‘metabolize’) energy. By targeting the adapted metabolic mechanisms which are common to most cancers, it makes it more difficult overall for cancer cells to survive, grow, and spread in the body.
|
AVRT
AVRT specializes in identifying and treating the early warning signs of cancer. Created by the physicians and scientists who developed the ground-breaking COC Protocol, AVRT uses a similar approach by identifying and targeting the inflammatory and metabolic pathways that may increase the risk of developing cancer and chronic disease and intervenes early to influence the metabolic pathways that could lead to disease progression.
|
Aristotle™, ColonSentry and BreastSentry tests were developed, and their performance characteristics determined by Stage Zero Life Sciences, Inc.; they have not been cleared or approved by the US Food and Drug Administration. The Prostate Health Index (phi) is an FDA approved blood test that can help differentiate prostate cancer from benign conditions in men with elevated PSA. The Aristotle, ColonSentry, BreastSentry and Prostate Health Index tests must be ordered by and used only in consultation with a healthcare provider.
